VolitionRx Limited (VNRX)
Oxford Ledge is still expanding full research coverage of VNRX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Volition develops blood-based epigenetic tests to detect and monitor cancers and sepsis, with products already available for veterinary and human diagnostic use.
SEC filings
- 8-K 3.02 2026-06-18
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-06-10
- DEF 14A Proxy statement for shareholder vote 2026-06-02
- 8-K Entry into material agreement 2026-05-22
- 8-K Departure/election of directors or officers 2026-05-15
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for VNRX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open VNRX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.